GT Biopharma, Inc.
GTBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $5,798 | $6,466 | $8,811 | $9,591 |
| G&A Expenses | $0 | $0 | $0 | $47,924 |
| SG&A Expenses | $8,566 | $7,110 | $12,446 | $47,924 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $14,364 | $13,576 | $21,257 | $57,515 |
| Operating Income | -$14,364 | -$13,576 | -$21,257 | -$57,515 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,202 | $5,979 | $373 | -$498 |
| Pre-Tax Income | -$13,162 | -$7,597 | -$20,884 | -$58,013 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$13,162 | -$7,597 | -$20,884 | -$58,013 |
| % Margin | – | – | – | – |
| EPS | -6.94 | -5.64 | -0.66 | -2.06 |
| % Growth | -23% | -754.5% | 68% | – |
| EPS Diluted | -6.94 | -5.64 | -0.66 | -2.06 |
| Weighted Avg Shares Out | 1,897 | 1,347 | 31,868 | 28,156 |
| Weighted Avg Shares Out Dil | 1,897 | 1,348 | 31,868 | 28,156 |
| Supplemental Information | – | – | – | – |
| Interest Income | $402 | $780 | $292 | $38 |
| Interest Expense | $0 | $213 | $8 | $718 |
| Depreciation & Amortization | $0 | $13,576 | $0 | $0 |
| EBITDA | -$13,162 | $5,979 | -$20,965 | -$57,477 |
| % Margin | – | – | – | – |